Full-Time
Posted on 10/1/2025
Cannabis cultivation, processing, and retailing
$22 - $24/hr
Chicago, IL, USA
Hybrid
Role is required to be in office 4-days a week and WFH 1-day, with a rotating schedule.
Cresco Labs grows, processes, and retails cannabis products in eleven states, serving adult-use and medical markets. Its products come from its own cultivation and manufacturing facilities and are sold under a portfolio of trusted brands to ensure consistency. It differentiates itself through vertical integration—grower, processor, retailer—operating in high-demand, well-regulated markets to maintain quality and supply. Its goal is to expand market presence while upholding responsible practices, collaborating with governments, using eco-friendly packaging, and delivering value to shareholders and communities.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Stock Options
Employee Discounts
Cresco Labs expands Ohio footprint with Sunnyside Bridgeport dispensary. Friday, Apr 10, 2026 6:40 am ET 1min read Cresco Labs has opened Sunnyside Bridgeport, its seventh dispensary in Ohio and 73rd nationwide. The dispensary is located in downtown Bridgeport and offers a wide selection of cannabis products from Cresco Labs' brand portfolio. Customers can shop in-store or online for convenient pickup, with the store open daily from 9 a.m. to 9 p.m. Cresco Labs aims to normalize and professionalize the cannabis industry through its CPG approach to building national brands and a customer-focused retail experience. Cresco Labs Inc. has opened Sunnyside Bridgeport, its seventh dispensary in Ohio and 73rd nationwide, marking continued expansion in the U.S. cannabis market. Located in downtown Bridgeport at 435 Main Street, the dispensary is housed in a former bank building and is expected to contribute to local economic development through job creation and tax revenue. The facility will offer both recreational and medicinal cannabis products, sourced from Cresco Labs' brand portfolio, with in-store and online ordering options available. The dispensary is projected to employ approximately 12-15 full-time and 10-12 part-time workers, with competitive wages and benefits for full-time employees, including health insurance and stock investment opportunities. Bridgeport officials have emphasized that hiring will prioritize local residents, aligning with the company's commitment to community engagement. Revenue from the dispensary will generate local tax contributions, with 3.4% of gross sales allocated to Bridgeport, which could provide significant funding for public services. The strategic location near state borders enhances the dispensary's accessibility to neighboring states, supporting broader market reach. Cresco Labs continues to strengthen its position in the Ohio market, where it holds the top retail market share and third-largest branded product share. The company's expansion strategy reflects its mission to normalize and professionalize the cannabis industry through a consumer-focused retail model and national brand development. Ask Aime: What is the impact of Cresco Labs' expansion on the Ohio cannabis market? Aime insights. Which companies have consistent earnings growth and high profit margins? Which of Cathie Wood's stocks is she holding at a loss, that are worth me buying at the bottom? Which stocks are commonly held by Cathie Wood and Pelosi? Give me three stocks in an uptrend with cumulative gains not exceeding 20% in the last month?
Cresco Labs has opened its seventh Ohio dispensary, Sunnyside Bridgeport, located at 435 Main Street in Bridgeport. The new location marks the company's 73rd dispensary nationwide. The store is situated in downtown Bridgeport near the Ohio River, close to I-70 and U.S. Route 40. It offers cannabis products from Cresco Labs' brand portfolio, including Cresco, Supply, Good News, Mindy's and Wonder, along with accessories. Customers aged 21 and older can shop in-store or order online for pickup. The dispensary operates daily from 9 a.m. to 9 p.m. CEO Charlie Bachtell said the opening brings the company's "education-first approach" to more consumers across Belmont County and the Ohio Valley region.
Cresco Labs faces a trimmed price target of CA$2.25 from CA$2.50 by Canaccord, which maintains a Speculative Buy rating despite elevated execution risk. The updated fair value estimate stands at CA$2.44, suggesting modest upside but reflecting cautious analyst sentiment on the company's near-term progress. The cannabis operator recently secured conditional approval for a vertically integrated medical cannabis licence in Texas, one of the largest potential markets in the US. Cresco also expanded its retail footprint through a partnership bringing Bloom's vape products into Pennsylvania's Sunnyside dispensaries. However, labour tensions emerged as workers at a Pennsylvania location voted to authorise a strike before reaching a new contract with higher wages and improved benefits after a 20-day work stoppage.
Cresco Labs has been conditionally awarded a vertically integrated Texas Compassionate Use Program licence, allowing the company to cultivate, process and dispense medical cannabis. The licence enables capital-efficient entry into Texas, America's second-most populous state with nearly 30 million residents. The merit-based award reflects Cresco Labs' regulatory expertise and approach to local engagement. CEO Charlie Bachtell said the company's track record in medical markets positions it to build robust programmes prioritising patients and communities. The licence advances Cresco Labs' state-by-state growth strategy, securing access to one of the largest patient populations in the US. Texas continues to see legislative efforts to improve patient access and broaden qualifying conditions for medical cannabis use.
Cresco Labs reported Q4 2025 revenue of $162 million and full-year revenue of $656 million. The cannabis company achieved adjusted EBITDA of $40 million in the quarter and $157 million for the year, with operating cash flow of $27 million in Q4. Adjusted gross margin improved to 52.2% in Q4, up from 48.8% in Q3. The company strengthened its balance sheet by refinancing debt with maturities extending to 2030 and exited the California market to focus on higher-return regions. Cresco maintained the top branded market share in Illinois, Pennsylvania and Massachusetts. However, wholesale revenue declined approximately 6% quarter-over-quarter. The company expects a high single-digit sequential revenue decline in Q1 2026 due to Michigan's excise tax changes and the California exit.